Associations between Single Nucleotide Polymorphisms of COX-2 and MMP-2 Genes and Colorectal Cancer Susceptibility in the Saudi Population |
Shalaby, Manal Ali
(Genetic Engineering and Biotechnology Research Institute (GEBRI), City for Scientific Research and Technology Applications)
Nounou, Howaida Attia (Department of Medical Biochemistry, Faculty of Medicine, Alexandria University) Alanazi, Mohammad Saud (Department of Biochemistry, College of Science, King Khalid University Hospital, King Saud University) Alharby, Othman (Department of Internal Medicine, Division of Gastroenterology, King Khalid University Hospital, King Saud University) Azzam, Nahla (Department of Internal Medicine, Division of Gastroenterology, King Khalid University Hospital, King Saud University) Saeed, Hesham Mahmoud (Institute of Graduate Studies and Research, Department of Bioscience and Technology, Alexandria University) |
1 | Zhang X, Miao X, Tan W, et al (2005). Identification offunctional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology, 129, 565-76, |
2 | Zhao F, Zhu H, Huang M, Yi C, Huang Y (2013), The 765G> C polymorphism in the cyclooxygenase-2 gene and gastric cancer risk: an update by meta-analysis. Asian Pac J Cancer Prev, 15, 2863-8. 과학기술학회마을 DOI |
3 | Wastson SA, Morriss TM, Robinson G, et al (1995). Inhibition of organ invasion by the matrix metalloproteinase inhibitor BB-94 (batimastat) in two human colon carcinoma metastasis models. Cancer Res, 55, 3629-33. |
4 | Tsujii M, Kawano S, DuBois RN (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA, 94, 3336-40 DOI ScienceOn |
5 | Wang X, Fu X, Brown PD, Crimmin MJ (1995). Foffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in a nude mice. Cancer Res, 54, 4726-8. |
6 | Wang D, Dubois RN (2006). Prostaglandins and cancer. Gut, 55, 115-22. DOI ScienceOn |
7 | Waston SA, Morriss TM, Parsons SL, Steele RJC, Brown PD (1996). Therapeutic effect of matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer, 74, 1354-8. DOI |
8 | Wu HC, Chang CH, Ke HL, et al (2011). Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan. Anticancer Res, 31, 221-25. |
9 | Wu CY, Wang CJ, Tseng CC (2005). Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway, World J Gastroenterol, 11, 3197-203. DOI |
10 | Xu E, Lai M, Lv B, et al (2004). A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun, 324, 999-1003. DOI ScienceOn |
11 | Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS (1997). Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Sur Res, 69, 367-71. DOI |
12 | Sanger F, Nicklen S, Coulson AR (1977). DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci U S A, 74, 5463-7, DOI ScienceOn |
13 | Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc BioI, 22, 1631-36. DOI ScienceOn |
14 | Ruud J, Nilsson A, Ruud L, Wang W, et al (2013). Cancerinduced anorexia in tumor-bearing mice is dependent on cyclooxygenase-1. Brain Behav Immun, 29, 124-35. DOI |
15 | Thiel A, Narko K., Heinonen M, HemmesA, Tomasetto C, Rio MC, Ristimaki A (2012). Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer, 131, 1032-41. DOI |
16 | Shahedi K, Lindstrom S, Zheng SL, et al (2006). Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer, 119, 668-72 DOI ScienceOn |
17 | Siironen P, Ristimaki A, Nordling S (2004). Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology, 44, 490-7. DOI ScienceOn |
18 | Sivula A, Talvensaari-Mattila A, Lundin J (2005). Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat, 89, 215-20, DOI |
19 | Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN (2006). Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell BioI, 38, 1654-61. DOI ScienceOn |
20 | Markowitz SD (2007). Aspirin and colon cancer-targeting prevention? N Engl J Med, 356, 2195-8. |
21 | Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67. DOI ScienceOn |
22 | Lacchini, R, Jacob-Ferreira AL, Luizon MR, et al (2012). Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens, 26,171-7. DOI |
23 | Langsenlelmer U, Yazdani-Biuki B, Eder T, et al (2006). The cyclooxygenase-2 (PIGS2) 8473T >C polymorphism is associated with breast cancer risk. Clin Cancer Res, 12, 1392-4. DOI |
24 | Oshima H, Oshima M, Inaba K (2004). Hyperplastic gastric tumours induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J, 23,1669-78. DOI ScienceOn |
25 | Masferrer JL, Leahy KM, KokiAT, et al (2006). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11. |
26 | Menter DG, Schilsky RL, DuBois RN (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res, 16, 1384-90. DOI ScienceOn |
27 | Oshima M, Dinchuk JE, Kargman SL (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-9. DOI ScienceOn |
28 | Ozhan G, Lochan R, Leathart JBS, Charnley R, Daly AK (2011). Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. Pancreas, 40, 1289-94. DOI |
29 | Greenhough A, Smartt HJ, Moore AE, et al (2009): The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30,377-86. DOI ScienceOn |
30 | Eberhart CE, Coffey RJ, Radhika A, et al (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-8. DOI |
31 | Ekambaram P, Lambiv W, Cazzolli R,Ashton W, Honn V (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer and Metastasis Reviews, 30, 397-408. DOI |
32 | Fradet V, Cheng I, Casey G, Witte JS (2009). Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res, 15, 2559-66. DOI |
33 | Hua H, Li M, Luo T, Yin Y, Jiang Y (2011). Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cellular and Molecular Life Sciences, 68, 3853-68. DOI |
34 | Gustafsson A, Hansson E, Kressner U, et al (2007). EPl-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer, 121, 232-40. DOI |
35 | Gustafsson A, Hansson E, Kressner U, et al (2007). Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol, 56, 1-6. |
36 | Hull MA, Ko SC, Hawcroft G (2004). Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther, 3,1031-39. DOI ScienceOn |
37 | Cheng I, Liu X, Plummer SJ, et al (2007). COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer, 97, 557-61. DOI ScienceOn |
38 | Chun S, Surh J (2014). Cancer chemoprevention targeting cox-2 using dietary phytochemicals, in 'Cancer and Inflammation Mechanisms: Chemical, Biological, and Clinical Aspects' (eds Y. Hiraku, S. Kawanishi and H. Ohshima), John Wiley & Sons, Inc., Hoooken, NJ, USA. |
39 | Church RD, Fleshman JW, McLeod HL (2003). Cyclooxygenase 2 inhibition in colorectal cancer therapy. Br J Surg, 90, 1055-67. DOI ScienceOn |
40 | Chan AT, Ogino S, Fuchs CS (2007). Aspirin and the risk of colorectal cancer in relation to the expression of COX -2. N Engl J Med, 356, 2131-42. DOI ScienceOn |
41 | Chulada PC, Thompson MB, Mahler JF (2000). Genetic disruption of Ptgs-l, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res, 60, 4705-8. |
42 | Brown JR, DuBois RN (2005). COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol, 23, 2840-55. DOI |
43 | Dossus L, Kaaks R, Canzian F, et al (2010). PTGS2 and IL6 genetic variation and risk of breast and protate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis, 31, 455-61 DOI ScienceOn |
44 | Amirian ES, Ittmann MM, Scheurer ME (2011). Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk. Prostate, 71, 1382-9. DOI ScienceOn |
45 | Asting G, Caren H, Andersson M, Lonnroth C, Lagerstedt K, Lundholm K (2011). COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status. BMC Cancer, 11, 1-10. DOI ScienceOn |
46 | Cahlin C, Lonnroth C, Arvidsson A, Nordgren S, Lundholm K (2008). Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol, 32, 909-18. |
47 | Campa D, Zienolddiny S, Maggini V, et al (2004). Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25, 229-35. |
48 | Chun KS, Surh Y (2004). Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacal, 68, 1089-1100. DOI ScienceOn |
49 | Pereira C, Medeiros RM, Dinis-Ribeiro MJ (2009). Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol, 21, 76-91. DOI ScienceOn |
50 | Price SJ, Greaves DR, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J BioI Chem, 276, 7549-58. DOI ScienceOn |
51 | Callejas NA, Casado M, Diaz-Guerra M (2001). Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology, 33, 860-7. DOI ScienceOn |
52 | Decock J, Paridaens R, Ye S (2008). Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet, 73, 197-211. |
53 | Song F, Wang L, HuangY, et al (2013). MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Asian Pac J Cancer Prev, 14, 7529-36, 과학기술학회마을 DOI ScienceOn |